Compare VSAT & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VSAT | VERA |
|---|---|---|
| Founded | 1986 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 3.0B |
| IPO Year | 1996 | 2021 |
| Metric | VSAT | VERA |
|---|---|---|
| Price | $67.37 | $34.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | $59.80 | ★ $81.30 |
| AVG Volume (30 Days) | 1.9M | ★ 2.1M |
| Earning Date | 05-19-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.42 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.32 | N/A |
| Revenue Next Year | $3.57 | $472.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.10 | $21.65 |
| 52 Week High | $93.03 | $56.05 |
| Indicator | VSAT | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 41.18 | 50.07 |
| Support Level | $67.49 | $33.43 |
| Resistance Level | $75.57 | $42.77 |
| Average True Range (ATR) | 3.40 | 1.83 |
| MACD | -1.33 | 0.64 |
| Stochastic Oscillator | 2.59 | 60.19 |
Viasat Inc an world-wide provider of communications technologies and services, focused on making connectivity accessible, available and secure for current and future customers world-wide. The company has two reportable segments: communication services and defense and advanced technologies. It generates majority of revenue from communication services segment provides a wide range of broadband and narrowband communications solutions across government and commercial mobility markets, as well as for residential and enterprise fixed broadband customers. It has presence in United States and Outside United States. The company generates majority of revenue from United States. Its products are Antennas, Terminals & radios, Modems, Semiconductors, Cybersecurity, Software & services, Home internet.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.